Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Midostaurin in patients with Acute Myeloid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin in combination with intermediate dose cytarabine consolidation chemotherapy for reimbursement as a treatment option for the treatment of adult patients newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation positive
This statement is based on a regulatory approval from the Health Service Executive:
Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive